Exhibit 10.1
Execution Version
SECOND AMENDMENT
SECOND AMENDMENT TO THE AMENDED AND RESTATED CREDIT AGREEMENT, dated as of November 8, 2024 (this “Agreement”), among MICROCHIP TECHNOLOGY INCORPORATED, a Delaware corporation (the “Borrower”), each Subsidiary Guarantor listed on the signature pages hereof, JPMorgan Chase Bank, N.A., as administrative agent for the Lenders (the “Administrative Agent”), the Lenders party hereto and the other parties party hereto.
W I T N E S S E T H
WHEREAS, reference is hereby made to the Amended and Restated Credit Agreement, dated as of December 16, 2021 (as amended by the First Incremental Term Loan Amendment dated as of August 31, 2023 and as further amended, restated, amended and restated, supplemented or otherwise modified from time to time prior to the date hereof, the “Credit Agreement” and as amended pursuant to this Agreement, the “Amended Credit Agreement”), among the Borrower, the Lenders party thereto from time to time, the Issuing Bank party thereto from time to time, JPMorgan Chase Bank, N.A., as administrative agent for the Lenders;
WHEREAS, pursuant to 9.02(a) of the Credit Agreement, the Borrower, the Administrative Agent and the Lenders party hereto wish to make amendments to the Credit Agreement reflected herein;
NOW, THEREFORE, the parties hereto agree as follows:
SECTION 1. Defined Terms. Unless otherwise defined herein, capitalized terms are used herein as defined in the Credit Agreement.
SECTION 2. Amendment of the Credit Agreement.
(a) On and as of the Second Amendment Effective Date upon the satisfaction or waiver of the conditions set forth in Section 3:
(i) Section 6.11(a) (Maximum Total Leverage Ratio) of the Credit Agreement shall be amended and restated as follows:
“The Borrower will not permit the ratio (the “Total Leverage Ratio”), determined as of the end of each of its fiscal quarters ending on and after the Restatement Effective Date, of (i) Consolidated Total Indebtedness to (ii) Consolidated EBITDA for the period of four (4) consecutive fiscal quarters ending with the end of such fiscal quarter, all calculated for the Borrower and its Subsidiaries on a consolidated basis, to be greater than: (A) 4.00 to 1.00 for any such period ended after the Restatement Effective Date to (but excluding) December 31, 2022, (B) 3.75 to 1.00 for any such period ended on or after December 31, 2022 to (but excluding) December 31, 2023, (C) 3.50 to 1.00 for any such period ended on or after December 31, 2023 (excluding the periods ended on December 31, 2024, March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025) and (D) 4.75 to 1.00 for any such period ended on December 31, 2024, March 31, 2025, June 30, 2025, September 30, 2025 or December 31, 2025, provided that, (i) solely for purposes of testing compliance with this clause (D) under clause (c) of the